(MENAFN- ProactiveInvestors - UK) Plant-based biotech iBio (NYSE:IBIO) today received a boost as it was allowed a patent extension to cover anthrax viruses under its iBioModulator system.
The iBioModulator platform is designed to make vaccines easier and cheaper to administer by reducing the overall costs and logistical difficulties of their use.
IBio says that the only vaccine for anthrax currently approved for use in the US requires an initial series of five doses to achieve adequate protection.
"This patent will provide further opportunities for commercial development of our iBioModulator platform for sub-unit vaccine products," said Robert Erwin, iBio's President.
"Application of this technology to anthrax is timely because of the threat posed by anthrax due to its potential use in bioterrorism and recent outbreaks among wildlife in the United States.
"There is a clear need for an improved vaccine for anthrax and for improved production methods that allow for safe, mass-production at a reasonable cost."
Robert B Kay, iBio's chairman and chief executive added: "The iBioModulator platform is separate and independent from our plant-based biologics technology.
"Although we recommend its use together with our iBioLaunch platform to achieve maximum efficiency in producing the fused protein, the iBioModulator is usable independently and is applicable to recombinant vaccines made with any system.
"We expect strong interest in its use by both corporate and government clients."
Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.